18F-FES PET/CT's Additional Clinical Value in ER+ BC

Completed

• Conditions: Breast Cancer

• Registration Number: NCT04006626
• Lead Sponsor: Fudan University

Brief Summary

To figure out whethetr 18F-FES PET/CT could influence the staging and management of newly diagnosed Oestrogen Receptor-positive Breast Cancer Patients.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2019-02-15
• Primary Completion: 2019-06-12
• Study Completion: 2019-06-20
• Study First Submitted: 2019-06-26
• Status Verified: 2019-07
• Study First Submitted QC: 2019-07-02
• Last Update Submitted: 2019-07-02
• Study First Posted: 2019-07-05
• Last Update Posted: 2019-07-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

• Patients with newly diagnosed immunohistochemical confirmed oestrogen receptor (ER)-positive breast cancer
• Patients underwent both 18F-FES PET/CT and 18F-FDG PET/CT in Fudan University Shanghai Cancer Center within 1 week after diagnosis
• Patients with available medical history

Read More

Exclusion Criteria

• Patients with incomplete medical history

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Staging of breast cancer	6 weeks	Deliver questionnaire to phycians to investigate the staging of BC according to AJCC 8 (TNM staging).

Trial Locations

Locations (1)

Biyun Wang, MD; 🇨🇳 Shanghai, Shanghai, China